

TABLE OF CONTENTS

	Page
ACKNOWLEDGEMENT	iii
ENGLISH ABSTRACT	iv
THAI ABSTRACT	vi
LIST OF TABLES	ix
LIST OF ILLUSTRATIONS	x
LIST OF ABBREVIATIONS	xii
INTRODUCTION	1
LITERATURE REVIEW	5
OBJECTIVES	17
MATERIALS AND METHODS	18
Drug formulations	18
Subjects	18
Study Design	21
Determination of Serum Theophylline Concentrations	23
Principle of Fluorescence Polarization Immunoassay	24
Data Analysis	25
RESULTS	28
DISCUSSION	57
CONCLUSION	61
REFERENCES	62
APPENDIX	68
VITA	76

LIST OF TABLES

Table	Page
1 Demographic characteristics of subject.	20
2 The randomized schedule of drug administration.	22
3 Serum theophylline concentrations ($\mu\text{g/ml}$) after a single oral dose of 400 mg Franol [®] .	29
4 Pharmacokinetic parameters of theophylline after a single oral dose of 400 mg Franol [®] .	31
5 Steady-state serum theophylline concentrations ($\mu\text{g/ml}$) after once daily doses of 400 mg Uni-Dur [®] .	36
6 Steady-state serum theophylline concentrations ($\mu\text{g/ml}$) after once daily doses of 2 X 200 mg Theo-Dur [®] .	37
7 Steady-state serum theophylline concentrations ($\mu\text{g/ml}$) after once daily doses of 400 mg Xanthium [®] .	38
8 Steady-state pharmacokinetic parameters of theophylline after once daily doses of 400 mg Uni-Dur [®] .	39
9 Steady-state pharmacokinetic parameters of theophylline after once daily doses of 2 x 200 mg Theo-Dur [®] .	40
10 Steady-state pharmacokinetic parameters of theophylline after once daily doses of 400 mg Xanthium [®] .	41
11 Comparison of steady-state pharmacokinetic parameters of Uni-Dur [®] , Theo-Dur [®] and Xanthium [®] .	42
12 Summary of parametric 90% confidential intervals (90%CI) of the mean steady-state pharmacokinetic parameters of Uni-Dur [®] , Theo-Dur [®] and Xanthium [®] .	43

LIST OF ILLUSTRATIONS

Figure	Page
1 Structural formula of anhydrous theophylline.	5
2 Pathway of theophylline metabolism.	12
3 Serum concentration-time curves after a single oral dose of 400 mg Franol [®] in 13 healthy Thai male subjects.	30
4 Mean serum concentration-time curves after a single oral dose of 400 mg Franol [®] in 13 healthy Thai male subjects.	30
5 Mean amount (%) of bioavailable drug absorbed with time (Wagner-Nelson method) after 400 mg oral dose of Franol [®] .	32
6 Mean amount (%) of drug remaining to be absorbed with time after 400 mg oral dose of Franol [®] .	32
7 Individual profiles of steady-state (Day6-Day7) serum concentration-time curves after once daily doses of 400 mg Uni-Dur [®] , Theo-Dur [®] , and Xanthium [®] .	44-46
8 Mean steady-state (Day6-Day7) serum theophylline concentration-time curves after once daily dose of 400 mg Uni-Dur [®] , Theo-Dur [®] , and Xanthium [®] .	47
9 Amount (%) of bioavailable drug absorbed with time (Wagner-Nelson method) after 400 mg oral dose(s) of Uni-Dur [®] , Theo-Dur [®] , Xanthium [®] and Franol [®] .	48-52
10 Mean amount (%) of bioavailable drug absorbed with time (Wagner-Nelson method) after 400 mg oral doses of Uni-Dur [®] .	53
11 Mean amount (%) of drug remaining to be absorbed with time after 400 mg oral doses of Uni-Dur [®] .	53

12	Mean amount (%) of bioavailable drug absorbed with time (Wagner-Nelson method) after 400 mg oral doses of Theo-Dur [®] .	54
13	Mean amount (%) of drug remaining to be absorbed with time after 2 x 200 mg oral doses of Theo-Dur [®] .	54
14	Mean amount (%) of bioavailable drug absorbed with time (Wagner-Nelson method) after 400 mg oral doses of Xanthium [®] .	55
15	Mean amount (%) of drug remaining to be absorbed with time after 400 mg oral doses of Xanthium [®] .	55
16	Mean amount (%) of bioavailable drug absorbed with time after 400 mg oral dose(s) of Uni-Dur [®] , Theo-Dur [®] , Xanthium [®] and Franol [®] .	56
17	Comparison of mean amount (%) of drug remaining to be absorbed with time after 400 mg oral dose(s) of Uni-Dur [®] , Theo-Dur [®] , Xanthium [®] and Franol [®] .	56

LIST OF ABBREVIATIONS

%CV	percent coefficient of variation
μg	microgram
$^{\circ}\text{C}$	degree celsius
90%CI	90% confidence interval
AUC _{ss}	area under the concentration-time curve at steady-state
BUN	blood urea nitrogen
BW	body weight
CL	clearance
cm	centimeter
C_{max}	maximum concentration
$C_{\text{ss}_{\text{max}}}$	steady-state maximum concentration
C_{min}	minimum concentration
$C_{\text{ss}_{\text{min}}}$	steady-state minimum concentration
conc.	concentration
dl	deciliter
e.v.	extravascular
Exp.	expired date
FPIA	fluorescence polarization immunoassay
F_{rel}	relative bioavailability
hr	hour
i.v.	intravascular
K_e	elimination rate constant
kg	kilogram
l	liter

Mfd.	manufactured date
mg	milligram
min	minute
ml	milliliter
MRT	mean residence time
nm	nanometer
no.	number
rpm	round per minute
SD	standard deviation
SE	standard error of mean
SRT	sustained-release tablet
STC	serum theophylline concentration
$T_{1/2}$	elimination half life
$T_{abs_{1/2}}$	time at which 50% of drug absorbed
T_{max}	time to reach maximum concentration
yr	year